Emergent Biosolutions (EBS) AI Stock Analysis

• Market Cap: $407.07M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): 3.1
• Beta (1Y): 3.21
• Revenue Growth: -22.74%
• EPS Growth: N/A
• Country: US
• Employees: 900
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.16
• Shares Outstanding: 53,351,097
• 10 Day Avg. Volume: 1,035,591
• 30 Day Avg. Volume: 1,328,909
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.84
• Enterprise Value/Revenue: 0.78
• Enterprise Value/Gross Profit: 2.47
• Enterprise Value/Ebitda: 7.06
• 1Y Price Target: $13.50
• Price Target Upside: 78.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: $8.00 ▲(5.54% Upside)

Emergent Biosolutions' overall stock score is driven by a positive earnings call that highlights financial improvements and strategic initiatives. However, financial performance remains a concern due to declining revenues and profitability. The stock's undervaluation and mixed technical signals also contribute to the score.

Positive Factors

Contract Awards

Emergent announced that it has received a $30M contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply CYFENDUS.

Financial Performance

Emergent also continued to make strides in improving its balance sheet, bolstered by $95 million in operating cash flow to date this year, helping the Company reduce its net debt to $433 million at the end of the second quarter.

Market Expansion

Emergent recently announced a $65M multi-year contract with Ontario Ministry of Health for NARCAN Nasal Spray.

Negative Factors

Generic Competition

Risks include faster-than-anticipated NARCAN franchise erosion due to greater-than-anticipated levels of generic competition.

Revenue Miss

Emergent recorded $140.9M in total top-line revenue, which missed the forecast of $192.1M.

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Emergent BioSolutions generates revenue through multiple streams, primarily from the sale of its vaccines and therapeutics in the Biodefense segment, which includes products like anthrax vaccines and botulinum antitoxin. The company also earns revenue from its Commercial segment, which focuses on providing contract development and manufacturing services for various pharmaceutical clients. Significant partnerships with government agencies, such as the U.S. Department of Health and Human Services, along with collaborations with private sector entities, contribute to a steady flow of contracts and funding, particularly for public health preparedness initiatives. Additionally, EBS benefits from licensing agreements and the commercialization of its proprietary products, which further bolster its earnings.

Emergent Biosolutions Financial Statement Overview

Summary

Emergent BioSolutions is facing financial challenges with declining revenue and profitability, negative net income, and shrinking margins. The balance sheet shows moderate leverage but declining equity, while cash flow is volatile despite some recovery.

Income Statement

Emergent Biosolutions has experienced a decline in revenue from 2021 to TTM 2025, coupled with negative net income over the past few periods, indicating profitability issues. The gross profit margin for TTM 2025 is approximately 31.6%, showing a decrease compared to historical figures. The company also faces challenges with negative EBIT and EBITDA margins, signaling operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio for TTM 2025 stands at approximately 1.20, indicating a moderate level of leverage. While the equity ratio is around 38.8%, showing a reasonable balance between equity and assets, the declining stockholders' equity over the years raises concerns about financial stability. The negative ROE underscores ongoing profitability challenges.

Cash Flow

Emergent Biosolutions shows a positive trend in operating cash flow for TTM 2025, with an operating cash flow to net income ratio of approximately -0.84, reflecting cash flow generation despite losses. The free cash flow has improved compared to previous years, suggesting some recovery in cash management. However, the significant fluctuations in cash flow metrics highlight potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	960.00M	1.01B	1.05B	1.12B	1.79B	1.56B
Gross Profit	303.40M	305.20M	343.90M	427.20M	1.04B	1.03B
EBITDA	106.30M	36.90M	-505.30M	-32.90M	458.20M	549.00M
Net Income	-131.60M	-190.60M	-760.50M	-223.80M	219.50M	305.80M
Balance Sheet
Total Assets	1.43B	1.39B	1.82B	3.17B	2.96B	2.88B
Cash, Cash Equivalents and Short-Term Investments	149.10M	99.50M	111.70M	642.60M	576.10M	621.30M
Total Debt	665.70M	663.70M	860.20M	1.41B	841.00M	874.80M
Total Liabilities	873.40M	906.90M	1.17B	1.78B	1.34B	1.44B
Stockholders Equity	552.70M	482.80M	649.30M	1.38B	1.62B	1.45B
Cash Flow
Free Cash Flow	94.40M	35.80M	-257.90M	-149.90M	96.10M	395.00M
Operating Cash Flow	110.10M	58.70M	-206.30M	-34.10M	321.10M	536.00M
Investing Cash Flow	195.50M	125.20M	212.30M	-381.30M	-225.00M	-151.00M
Financing Cash Flow	-231.10M	-190.00M	-535.70M	481.20M	-141.00M	69.50M

Emergent Biosolutions Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Neutral. The current price of 7.58 is below the 20-day moving average (MA) of 8.63, above the 50-day MA of 7.55, and above the 200-day MA of 7.43, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of 3.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EBS.

Emergent Biosolutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	82 Outperform	$607.93M	7.39	43.61%	10.13%	3.86%	-2.60%
ANIP	66 Neutral	$2.08B	―	-2.82%	―	38.68%	-160.14%
EBS	61 Neutral	$407.07M	3.09	30.24%	―	-22.74%	―
AQST	56 Neutral	$612.13M	―	77.48%	―	-24.38%	-94.72%
DVAX	54 Neutral	$1.17B	64.45	-9.28%	―	26.66%	-419.55%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
LFCR	49 Neutral	$297.02M	―	-76.41%	―	0.47%	-430.88%

Emergent Biosolutions Corporate Events

Emergent BioSolutions Secures $30M BARDA Contract Extension

On August 29, 2025, Emergent BioSolutions received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of CYFENDUS™, an anthrax vaccine. This contract, part of an ongoing agreement since 2016, underscores Emergent’s commitment to supporting U.S. national security priorities by ensuring the availability of medical countermeasures against anthrax threats. The deliveries are expected to start within the current calendar year and conclude by March 2026, highlighting Emergent’s strategic role in biodefense.

Emergent BioSolutions Surpasses Q2 Revenue Expectations

Emergent BioSolutions reported its financial results for the second quarter of 2025, with total revenues of $140.9 million, surpassing guidance by $21 million. Despite a net loss of $12 million, the company showed significant improvements in profitability and margins compared to the previous year. The company raised its full-year profitability guidance and secured several government contracts, reinforcing its position in the medical countermeasures market.

Emergent BioSolutions Secures $62.4M ASPR Contract Modification

On June 23, 2025, Emergent BioSolutions announced a $62.4 million contract modification with the Administration for Strategic Preparedness and Response (ASPR) for the supply of BAT®, a botulism antitoxin. This contract modification underscores the U.S. government’s commitment to stockpiling medical countermeasures and highlights Emergent’s role in strengthening global emergency preparedness and public health protection.